We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Show more
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
-- Presented initial in vivo data for universal liver-targeted LNP and Wilsonโs Disease program at ESGCT; initiated IND-enabling activities for Wilsonโs Disease program in 4Q 2024 and remains on...
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -4.1095890411 | 2.92 | 3.34 | 2.755 | 949040 | 3.07630174 | CS |
4 | -0.12 | -4.1095890411 | 2.92 | 3.59 | 2.63 | 842330 | 3.03586899 | CS |
12 | -1.29 | -31.5403422983 | 4.09 | 4.71 | 2.56 | 1126129 | 3.20644435 | CS |
26 | -2.82 | -50.1779359431 | 5.62 | 5.94 | 2.56 | 1212155 | 3.64493376 | CS |
52 | -3.85 | -57.8947368421 | 6.65 | 9.77 | 2.56 | 1017856 | 4.79149822 | CS |
156 | -16.17 | -85.2398523985 | 18.97 | 21.7301 | 2.56 | 653932 | 7.11072855 | CS |
260 | -16.17 | -85.2398523985 | 18.97 | 21.7301 | 2.56 | 653932 | 7.11072855 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions